Blurbs

SVB Securities Sticks to Its Hold Rating for Agios Pharma (AGIO)

In a report issued on May 5, Andrew Berens from SVB Securities maintained a Hold rating on Agios Pharma (AGIOResearch Report), with a price target of $30.00. The company’s shares closed last Friday at $22.62, close to its 52-week low of $21.72.

According to TipRanks.com, Berens ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -13.5% and a 36.1% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.

Currently, the analyst consensus on Agios Pharma is a Moderate Buy with an average price target of $48.33.

See the top stocks recommended by analysts >>

Agios Pharma’s market cap is currently $1.24B and has a P/E ratio of -3.56.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Read More on AGIO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos